Aby J. Mathew Sells 10,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

BioLife Solutions Price Performance

Shares of BLFS opened at $23.14 on Friday. BioLife Solutions, Inc. has a twelve month low of $8.92 and a twelve month high of $26.73. The stock’s 50 day moving average is $24.64 and its two-hundred day moving average is $21.72. The firm has a market capitalization of $1.07 billion, a PE ratio of -16.30 and a beta of 1.88. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. Research analysts anticipate that BioLife Solutions, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

BLFS has been the subject of several research analyst reports. Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. TD Cowen upped their target price on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Craig Hallum upped their target price on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, HC Wainwright initiated coverage on shares of BioLife Solutions in a report on Monday, September 30th. They issued a “buy” rating and a $29.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the company. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $35,000. Isthmus Partners LLC boosted its stake in shares of BioLife Solutions by 34.4% during the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Register Financial Advisors LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter worth approximately $96,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $122,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.